{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T18:29:34Z","timestamp":1788719374427,"version":"build-2803163510"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI131430"],"award-info":[{"award-number":["R01AI131430"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI162246"],"award-info":[{"award-number":["R01AI162246"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI140799"],"award-info":[{"award-number":["R01AI140799"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"},{"DOI":"10.13039\/100006108","name":"U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["KL2TR001109-04"],"award-info":[{"award-number":["KL2TR001109-04"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["DGE-1650116"],"award-info":[{"award-number":["DGE-1650116"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ultra-long-acting delivery platforms for HIV pre-exposure prophylaxis (PrEP) may increase adherence and maximize public health benefit. We report on an injectable, biodegradable, and removable in-situ forming implant (ISFI) that is administered subcutaneously and can release the integrase inhibitor cabotegravir (CAB) above protective benchmarks for more than 6 months. CAB ISFIs are well-tolerated in female mice and female macaques showing no signs of toxicity or chronic inflammation. In macaques, median plasma CAB concentrations exceed established PrEP protection benchmarks within 3 weeks and confer complete protection against repeated rectal SHIV challenges. Implant removal via a small incision in 2 macaques at week 12 results in a 7- to 48-fold decrease in plasma CAB levels within 72\u2009hours. Modeling to translate CAB ISFI dosing suggests that a 3\u2009mL injection would exceed protective benchmarks in humans for over 5 months post administration. Our results support the clinical advancement of CAB ISFIs for ultra-long-acting PrEP in humans.<\/jats:p>","DOI":"10.1038\/s41467-023-36330-5","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T09:43:59Z","timestamp":1675935839000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Ultra-long-acting in-situ forming implants with cabotegravir protect female macaques against rectal SHIV infection"],"prefix":"10.1038","volume":"14","author":[{"given":"Isabella C.","family":"Young","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Massud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackenzie L.","family":"Cottrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roopali","family":"Shrivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panita","family":"Maturavongsadit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alka","family":"Prasher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7997-6126","authenticated-orcid":false,"given":"Andres","family":"Wong-Sam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuong","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiancheng","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Mrotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josilene Nascimento","family":"Seixas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aryani","family":"Pallerla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Thorson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Schauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Sykes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"De la Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8012-5302","authenticated-orcid":false,"given":"Stephanie A.","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela D. M.","family":"Kashuba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Heneine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9194-1775","authenticated-orcid":false,"given":"Charles W.","family":"Dobard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Kovarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3726-0482","authenticated-orcid":false,"given":"J. Victor","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6437-7745","authenticated-orcid":false,"given":"J. Gerardo","family":"Garc\u1f77a-Lerma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4738-5871","authenticated-orcid":false,"given":"S. Rahima","family":"Benhabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,9]]},"reference":[{"key":"36330_CR1","unstructured":"UNAIDS. Global HIV & AIDS statistics \u2014 2021 fact sheet, https:\/\/www.unaids.org\/en\/resources\/fact-sheet."},{"key":"36330_CR2","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMoa1108524","volume":"367","author":"JM Baeten","year":"2012","unstructured":"Baeten, J. M. et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N. Engl. J. Med. 367, 399\u2013410, https:\/\/doi.org\/10.1056\/NEJMoa1108524 (2012).","journal-title":"N. Engl. J. Med."},{"key":"36330_CR3","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1056\/NEJMoa1110711","volume":"367","author":"MC Thigpen","year":"2012","unstructured":"Thigpen, M. C. et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N. Engl. J. Med. 367, 423\u2013434, https:\/\/doi.org\/10.1056\/NEJMoa1110711 (2012).","journal-title":"N. Engl. J. Med."},{"key":"36330_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3463-4","volume":"18","author":"D Sidebottom","year":"2018","unstructured":"Sidebottom, D., Ekstrom, A. M. & Stromdahl, S. A systematic review of adherence to oral pre-exposure prophylaxis for HIV\u2014how can we improve uptake and adherence? BMC Infect. Dis. 18, 581 (2018).","journal-title":"BMC Infect. Dis."},{"key":"36330_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25408","volume":"22","author":"EE Tolley","year":"2019","unstructured":"Tolley, E. E. et al. Acceptability of a long-acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076). J. Int. AIDS Soc. 22, e25408 (2019).","journal-title":"J. Int. AIDS Soc."},{"key":"36330_CR6","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1097\/QAI.0b013e31819675e9","volume":"50","author":"VD Lima","year":"2009","unstructured":"Lima, V. D. et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J. Acquir Immune Defic. Syndr. 50, 529\u2013536 (2009).","journal-title":"J. Acquir Immune Defic. Syndr."},{"key":"36330_CR7","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1080\/17425247.2020.1783233","volume":"17","author":"DA Cobb","year":"2020","unstructured":"Cobb, D. A., Smith, N. A., Edagwa, B. J. & McMillan, J. M. Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research. Expert Opin. Drug Deliv. 17, 1227\u20131238 (2020).","journal-title":"Expert Opin. Drug Deliv."},{"key":"36330_CR8","unstructured":"Balasubramanian, R. et al. Conference on Retroviruses and Opportunisitc Infections (CROI)."},{"key":"36330_CR9","doi-asserted-by":"publisher","first-page":"S222","DOI":"10.1097\/QAI.0000000000002215","volume":"82","author":"AM Minnis","year":"2019","unstructured":"Minnis, A. M., Montgomery, E. T., Napierala, S., Browne, E. N. & van der Straten, A. Insights for implementation science from 2 multiphased studies with end-users of potential multipurpose prevention technology and HIV prevention products. J. Acquir Immune Defic. Syndr. 82, S222\u2013S229 (2019).","journal-title":"J. Acquir Immune Defic. Syndr."},{"key":"36330_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25094","volume":"21","author":"A van der Straten","year":"2018","unstructured":"van der Straten, A. et al. The Tablets, Ring, Injections as Options (TRIO) study: what young African women chose and used for future HIV and pregnancy prevention. J. Int. AIDS Soc. 21, e25094 (2018).","journal-title":"J. Int. AIDS Soc."},{"key":"36330_CR11","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1007\/s10461-018-2078-5","volume":"22","author":"AM Minnis","year":"2018","unstructured":"Minnis, A. M. et al. Young women\u2019s ratings of three placebo multipurpose prevention technologies for HIV and pregnancy prevention in a randomized, cross-over study in Kenya and South Africa. AIDS Behav. 22, 2662\u20132673 (2018).","journal-title":"AIDS Behav."},{"key":"36330_CR12","unstructured":"FDA. FDA approves first injectable treatment for HIV pre-exposure prevention, https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention (2021)."},{"key":"36330_CR13","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1093\/infdis\/jiab152","volume":"224","author":"MA Marzinke","year":"2021","unstructured":"Marzinke, M. A. et al. Characterization of Human Immunodeficiency Virus (HIV) infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for HIV prevention: HPTN 083. J. Infect. Dis. 224, 1581\u20131592 (2021).","journal-title":"J. Infect. Dis."},{"key":"36330_CR14","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2101016","volume":"385","author":"RJ Landovitz","year":"2021","unstructured":"Landovitz, R. J. et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N. Engl. J. Med. 385, 595\u2013608 (2021).","journal-title":"N. Engl. J. Med."},{"key":"36330_CR15","unstructured":"Landovitz, R. Conference on Retroviruses and Opportunistic Infections. (ed 2021 virtual. Abstract 153 Abstracts of the Conference on Retroviruses and Opportunistic Infections) (2021)."},{"key":"36330_CR16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/COH.0000000000000168","volume":"10","author":"C Trezza","year":"2015","unstructured":"Trezza, C., Ford, S. L., Spreen, W., Pan, R. & Piscitelli, S. Formulation and pharmacology of long-acting cabotegravir. Curr. Opin. HIV AIDS 10, 239\u2013245 (2015).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"36330_CR17","doi-asserted-by":"publisher","first-page":"e1002690","DOI":"10.1371\/journal.pmed.1002690","volume":"15","author":"RJ Landovitz","year":"2018","unstructured":"Landovitz, R. J. et al. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med. 15, e1002690 (2018).","journal-title":"PLoS Med."},{"key":"36330_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-018-0440-3","volume":"15","author":"M Oliveira","year":"2018","unstructured":"Oliveira, M. et al. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir. Retrovirology 15, 56 (2018).","journal-title":"Retrovirology"},{"key":"36330_CR19","doi-asserted-by":"publisher","first-page":"e472","DOI":"10.1016\/S2352-3018(20)30106-5","volume":"7","author":"RJ Landovitz","year":"2020","unstructured":"Landovitz, R. J. et al. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. Lancet HIV 7, e472\u2013e481 (2020).","journal-title":"Lancet HIV"},{"key":"36330_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12141-5","volume":"10","author":"SR Benhabbour","year":"2019","unstructured":"Benhabbour, S. R. et al. Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery. Nat. Commun. 10, 4324 (2019).","journal-title":"Nat. Commun."},{"key":"36330_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06490-w","volume":"9","author":"M Kovarova","year":"2018","unstructured":"Kovarova, M. et al. Ultra-long-acting removable drug delivery system for HIV treatment and prevention. Nat. Commun. 9, 4156 (2018).","journal-title":"Nat. Commun."},{"key":"36330_CR22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2174\/187221107779814113","volume":"1","author":"K Al-Tahami","year":"2007","unstructured":"Al-Tahami, K. & Singh, J. Smart polymer based delivery systems for peptides and proteins. Recent Pat. Drug Deliv. Formul. 1, 65\u201371 (2007).","journal-title":"Recent Pat. Drug Deliv. Formul."},{"key":"36330_CR23","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/(SICI)1097-4636(20000605)50:3<388::AID-JBM13>3.0.CO;2-F","volume":"50","author":"RE Eliaz","year":"2000","unstructured":"Eliaz, R. E. & Kost, J. Characterization of a polymeric PLGA-injectable implant delivery system for the controlled release of proteins. J. Biomed. Mater. Res. 50, 388\u2013396 (2000).","journal-title":"J. Biomed. Mater. Res."},{"key":"36330_CR24","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jconrel.2013.08.024","volume":"172","author":"M Parent","year":"2013","unstructured":"Parent, M. et al. PLGA in situ implants formed by phase inversion: critical physicochemical parameters to modulate drug release. J. Control Release 172, 292\u2013304 (2013).","journal-title":"J. Control Release"},{"key":"36330_CR25","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.drudis.2013.01.013","volume":"18","author":"P Agarwal","year":"2013","unstructured":"Agarwal, P. & Rupenthal, I. D. Injectable implants for the sustained release of protein and peptide drugs. Drug Discov. Today 18, 337\u2013349 (2013).","journal-title":"Drug Discov. Today"},{"key":"36330_CR26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jconrel.2013.12.020","volume":"176","author":"RR Thakur","year":"2014","unstructured":"Thakur, R. R., McMillan, H. L. & Jones, D. S. Solvent induced phase inversion-based in situ forming controlled release drug delivery implants. J. Control Release 176, 8\u201323 (2014).","journal-title":"J. Control Release"},{"key":"36330_CR27","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/jbm.a.32724","volume":"94","author":"RB Patel","year":"2010","unstructured":"Patel, R. B., Carlson, A. N., Solorio, L. & Exner, A. A. Characterization of formulation parameters affecting low molecular weight drug release from in situ forming drug delivery systems. J. Biomed. Mater. Res. A 94, 476\u2013484 (2010).","journal-title":"J. Biomed. Mater. Res. A"},{"key":"36330_CR28","doi-asserted-by":"publisher","first-page":"72","DOI":"10.4103\/0975-7406.67003","volume":"2","author":"G Tiwari","year":"2010","unstructured":"Tiwari, G., Tiwari, R. & Rai, A. K. Cyclodextrins in delivery systems: applications. J. Pharm. Bioallied Sci. 2, 72\u201379 (2010).","journal-title":"J. Pharm. Bioallied Sci."},{"key":"36330_CR29","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3390\/pharmaceutics14030615","volume":"14","author":"JB Joiner","year":"2022","unstructured":"Joiner, J. B. et al. Effects of injection volume and route of administration on dolutegravir in situ forming implant pharmacokinetics. Pharmaceutics 14, 615 (2022).","journal-title":"Pharmaceutics"},{"key":"36330_CR30","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3390\/pharmaceutics14061188","volume":"14","author":"JB Joiner","year":"2022","unstructured":"Joiner, J. B. et al. Effects of drug physicochemical properties on in-situ forming implant polymer degradation and drug release kinetics. Pharmaceutics 14, 118 (2022).","journal-title":"Pharmaceutics"},{"key":"36330_CR31","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/polym3031377","volume":"3","author":"HK Makadia","year":"2011","unstructured":"Makadia, H. K. & Siegel, S. J. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers 3, 1377\u20131397 (2011).","journal-title":"Polymers"},{"key":"36330_CR32","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/jps.21415","volume":"98","author":"R Astaneh","year":"2009","unstructured":"Astaneh, R., Erfan, M., Moghimi, H. & Mobedi, H. Changes in morphology of in situ forming PLGA implant prepared by different polymer molecular weight and its effect on release behavior. J. Pharm. Sci. 98, 135\u2013145 (2009).","journal-title":"J. Pharm. Sci."},{"key":"36330_CR33","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.jconrel.2012.04.016","volume":"161","author":"S Kempe","year":"2012","unstructured":"Kempe, S. & Mader, K. In situ forming implants\u2014an attractive formulation principle for parenteral depot formulations. J. Control Release 161, 668\u2013679 (2012).","journal-title":"J. Control Release"},{"key":"36330_CR34","first-page":"1216","volume":"20","author":"BD LaMarca","year":"2007","unstructured":"LaMarca, B. D. et al. Role of sex steroids in modulating tumor necrosis factor alpha-induced changes in vascular function and blood pressure. Am. J. Hypertens. 20, 1216\u20131221 (2007).","journal-title":"Am. J. Hypertens."},{"key":"36330_CR35","first-page":"1","volume":"6","author":"R Gouda","year":"2017","unstructured":"Gouda, R., Baishya, H. & Qing, Z. Application of mathematical models in drug release kinetics of Carbidopa and Levodopa ER tablets. J. Dev. Drugs 6, 1\u20138 (2017).","journal-title":"J. Dev. Drugs"},{"key":"36330_CR36","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jconrel.2016.10.009","volume":"243","author":"C Hernandez","year":"2016","unstructured":"Hernandez, C. et al. Macroporous acrylamide phantoms improve prediction of in vivo performance of in situ forming implants. J. Control Release 243, 225\u2013231 (2016).","journal-title":"J. Control Release"},{"key":"36330_CR37","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1007\/s10439-017-1926-1","volume":"45","author":"C Manaspon","year":"2017","unstructured":"Manaspon, C. et al. Increasing distribution of drugs released from in situ forming PLGA implants using therapeutic ultrasound. Ann. Biomed. Eng. 45, 2879\u20132887 (2017).","journal-title":"Ann. Biomed. Eng."},{"key":"36330_CR38","unstructured":"Spreen, W. et al. Conference on Retroviruses and Opportunistic Infections (CROI) (2019)."},{"key":"36330_CR39","unstructured":"FDA. Center for Drug Evaluation and Research Integrated Review: Application Number 212887Orig1s000 (2021)."},{"key":"36330_CR40","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1126\/science.1248707","volume":"343","author":"CD Andrews","year":"2014","unstructured":"Andrews, C. D. et al. Long-acting integrase inhibitor protects macaques from intrarectal simian\/human immunodeficiency virus. Science 343, 1151\u20131154 (2014).","journal-title":"Science"},{"key":"36330_CR41","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.jconrel.2020.12.024","volume":"330","author":"D Karunakaran","year":"2021","unstructured":"Karunakaran, D. et al. Design and testing of a cabotegravir implant for HIV prevention. J. Control Release 330, 658\u2013668 (2021).","journal-title":"J. Control Release"},{"key":"36330_CR42","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.biomaterials.2017.10.023","volume":"151","author":"T Zhou","year":"2018","unstructured":"Zhou, T. et al. Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials 151, 53\u201365 (2018).","journal-title":"Biomaterials"},{"key":"36330_CR43","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/s41563-020-0674-z","volume":"19","author":"TA Kulkarni","year":"2020","unstructured":"Kulkarni, T. A. et al. A year-long extended release nanoformulated cabotegravir prodrug. Nat. Mater. 19, 910\u2013920 (2020).","journal-title":"Nat. Mater."},{"key":"36330_CR44","doi-asserted-by":"publisher","first-page":"270ra275","DOI":"10.1126\/scitranslmed.3010297","volume":"7","author":"J Radzio","year":"2015","unstructured":"Radzio, J. et al. The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge. Sci. Transl. Med. 7, 270ra275 (2015).","journal-title":"Sci. Transl. Med."},{"key":"36330_CR45","doi-asserted-by":"crossref","unstructured":"Shaik, J. S. et al Multicompartmental pharmacokinetic evaluation of long-acting cabotegravir in healthy adults for HIV preexposure prophylaxis. Br. J. Clin. Pharmacol. 88, 1667\u20131678 (2022).","DOI":"10.1111\/bcp.14980"},{"key":"36330_CR46","doi-asserted-by":"publisher","first-page":"270ra274","DOI":"10.1126\/scitranslmed.3010298","volume":"7","author":"CD Andrews","year":"2015","unstructured":"Andrews, C. D. et al. A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge. Sci. Transl. Med. 7, 270ra274 (2015).","journal-title":"Sci. Transl. Med."},{"key":"36330_CR47","unstructured":"Marzinke, M. et al. Conference on Retroviruses and Opportunisitic Infections (2021)."},{"key":"36330_CR48","unstructured":"Landovitz, R. J. et al. Conference on Retroviruses and Opportunistic Infections (2019)."},{"key":"36330_CR49","unstructured":"CDC. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States\u20142021 Update, https:\/\/www.cdc.gov\/hiv\/pdf\/risk\/prep\/cdc-hiv-prep-guidelines-2021.pdf (2021)."},{"key":"36330_CR50","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1177\/1091581815622442","volume":"35","author":"SC Gad","year":"2016","unstructured":"Gad, S. C. et al. Tolerable levels of nonclinical vehicles and formulations used in studies by multiple routes in multiple species with notes on methods to improve utility. Int J. Toxicol. 35, 95\u2013178 (2016).","journal-title":"Int J. Toxicol."},{"key":"36330_CR51","unstructured":"Gaylord Chemical Company LLC. DMSO Health & Safety, https:\/\/www.gaylordchemical.com\/environmental-health-safety\/dmso-health-safety\/ (2021)."},{"key":"36330_CR52","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1208\/s12249-013-9960-2","volume":"14","author":"P Liu","year":"2013","unstructured":"Liu, P. et al. Dissolution studies of poorly soluble drug nanosuspensions in non-sink conditions. AAPS PharmSciTech 14, 748\u2013756 (2013).","journal-title":"AAPS PharmSciTech"},{"key":"36330_CR53","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s13346-011-0054-y","volume":"2","author":"L Solorio","year":"2012","unstructured":"Solorio, L., Olear, A. M., Zhou, H., Beiswenger, A. C. & Exner, A. A. Effect of cargo properties on in situ forming implant behavior determined by noninvasive ultrasound imaging. Drug Deliv. Transl. Res. 2, 45\u201355 (2012).","journal-title":"Drug Deliv. Transl. Res."},{"key":"36330_CR54","first-page":"89","volume":"81","author":"L Greenspan","year":"1997","unstructured":"Greenspan, L. Humidity fixed points of binary saturated aqueous solutions. J. Res. Natl Bur. Stand.- A. Phys. Chem. 81, 89\u201396 (1997).","journal-title":"J. Res. Natl Bur. Stand.- A. Phys. Chem."},{"key":"36330_CR55","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/QAD.0000000000003059","volume":"36","author":"SA Vishwanathan","year":"2022","unstructured":"Vishwanathan, S. A. et al. Sexually transmitted infections and depot medroxyprogesterone acetate do not impact protection from simian HIV acquisition by long-acting cabotegravir in macaques. AIDS 36, 169\u2013176 (2022).","journal-title":"AIDS"},{"key":"36330_CR56","doi-asserted-by":"publisher","first-page":"14ra14","DOI":"10.1126\/scitranslmed.3000391","volume":"2","author":"JG Garc\u00eda-Lerma","year":"2010","unstructured":"Garc\u00eda-Lerma, J. G. et al. Intermittent prophylaxis with oral truvada protects macaques form rectal SHIV infection. Sci. Transl. Med. 2, 14ra14 (2010).","journal-title":"Sci. Transl. Med."},{"key":"36330_CR57","doi-asserted-by":"publisher","first-page":"102894","DOI":"10.1016\/j.ebiom.2020.102894","volume":"58","author":"I Massud","year":"2020","unstructured":"Massud, I. et al. Single oral dose for HIV pre or post-exposure prophylaxis: user desirability and biological efficacy in macaques. EBioMedicine 58, 102894 (2020).","journal-title":"EBioMedicine"},{"key":"36330_CR58","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1600-0536.2011.01912.x","volume":"65","author":"MA Farage","year":"2011","unstructured":"Farage, M. A. et al. Historical perspective on the use of visual grading scales in evaluating skin irritation and sensitization. Contact Dermat. 65, 65\u201375 (2011).","journal-title":"Contact Dermat."},{"key":"36330_CR59","doi-asserted-by":"publisher","first-page":"643","DOI":"10.4155\/tde.11.19","volume":"2","author":"JA Yanez","year":"2011","unstructured":"Yanez, J. A., Remsberg, C. M., Sayre, C. L., Forrest, M. L. & Davies, N. M. Flip-flop pharmacokinetics\u2013delivering a reversal of disposition: challenges and opportunities during drug development. Ther. Deliv. 2, 643\u2013672 (2011).","journal-title":"Ther. Deliv."}],"updated-by":[{"DOI":"10.1038\/s41467-024-45552-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T00:00:00Z","timestamp":1707091200000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-36330-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-36330-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-36330-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T08:03:11Z","timestamp":1707206591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-36330-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,9]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["36330"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-36330-5","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41467-024-45552-0","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,9]]},"assertion":[{"value":"16 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41467-024-45552-0","URL":"https:\/\/doi.org\/10.1038\/s41467-024-45552-0","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.R.B., I.C.Y., R.S., and P.M. are inventors on a patent describing the Injectable Polymer Based Drug Formulation for Ultra-Long-Acting Drug Delivery. J.G.G.-L. and W.H. are named in US. Government patents on \u201cInhibition of HIV infection through chemoprophylaxis\u201d. J.G.G.-L.,. I.M., and W.H. are named in a US. Government patent on \u201cHIV postexposure prophylaxis\u201d and a US. Government patent application on \u201cHIV pre-exposure prophylaxis\u201d. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"708"}}